Module 1: Introduction and Welcome note: Dr Shubhi from Medical Learning Hub welcomed all participants, speakers and the chief guest. She shared details of the webinar and provided general instructions. The first poll was raised.

Module 2: Inaugral address: Dr Kuldeep Sachdeva, Chiefvguest of the CME inaugrated the session describing about thevision about the ManageTB India app and the journey of the development of the app

Module 3: Manage TB India app: Dr Rupak Singla discussed about the ManageTB India app and its features. Outlines of the discussion were:

• Need of ManageTB India application
• Process of app development
• Flow of the app
• Content of the app
• Validation workshops at Delhi and Himachal Pradesh
• Feedbacks of the users

Module 4: Case based discussion on DRTB: Dr Vikas Oswal talked about the management of DRTB in India. Key points of discussion were:

• MDR-TB Regimen Decision
• Gene expert results indicating Rif resistance can lead to labeling the patient as MDR-TB due to the high correlation with Isoniazid resistance.
• Sample sent for first and second LPA  and pre-treatment evaluations.
• Shorter Oral BDQ Regimen
• Specific Mutation Considerations
• Resistance patterns guide regimen adjustments, with drugs like Bedaquiline and Levofloxacin being considered.
• Treatment Duration
• Adjustments for Toxicities:
• Adjustments may be made to drug dosages or specific drugs to manage potential toxicities and patient response during the treatment process.

Module 5: Q & A: Several questions were asked from the participants which were all answered by Dr Vikas Oswal and Dr Rupak Singla

Module 6: Vote of thanks: Dr Shubhi from Medical Learning Hub delivered vote of thanks. Second poll was raised.
We wish you a great learning experience!

We thank Mylan Pharmaceuticals Private Limited, a Viatris Company for supporting us in the webinar.